Applied Therapeutics Ratios (2023-2025) | APLT

Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -99.78%3,096.85%-10,253.50%-13,758.33%-23,267.21%-1,661.40%
EBIT Margin -101.86%3,149.63%-10,546.50%-14,194.44%-24,379.51%-1,675.80%
EBITDA Margin -101.86%3,149.63%-10,546.50%-14,194.44%-24,379.51%-1,675.80%
Operating Margin -101.86%3,149.63%-10,546.50%-14,194.44%-24,379.51%-1,675.80%
Net Margin -95.09%5,649.03%-41,969.00%-13,758.33%-23,267.21%-1,661.40%
FCF Margin -65.57%2,549.48%-9,455.50%-15,690.97%-19,122.95%-1,840.10%
Efficiency
Assets Average 36.83M44.42M50.01M103.03M139.51M117.17M96.63M71.80M47.12M35.86M
Equity Average -4.20M-7.69M-14.10M25.07M69.84M39.14M31.45M46.84M27.05M8.44M
Invested Capital -4.07M-4.33M-11.04M-17.15M67.29M72.39M5.89M57.01M36.67M17.44M-0.56M
Asset Utilization Ratio 0.200.000.000.000.000.000.000.03
Leverage & Solvency
Equity Ratio -0.14-0.10-0.24-0.310.440.570.060.660.640.47-0.02
Valuation
Enterprise Value -22.92M-35.62M-37.50M-49.90M-146.50M-122.20M-98.90M-79.40M-50.80M-30.42M-11.95M
Return Ratios
Return on Sales -1.00%30.97%-102.54%-137.58%-232.67%-216.23%-395.35%-885.93%-16.61%
Return on Capital Employed 3.05%-3.91%-0.93%-5.07%-1.50%-2.02%-3.79%-33.29%
Return on Assets -1.26%-0.71%-0.55%-0.76%-1.04%-1.46%-2.29%-2.69%
Return on Equity 4.48%-2.91%-1.09%-2.28%-3.20%-2.25%-4.00%-11.41%